GlassScriptPhysician profile
Jeffrey A Murray
NPI 1457356529
$3,585.97
in general payments reported to CMS, 2019-2025
14 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.45 · 2020: $299 · 2021: $235 · 2022: $239 · 2023: $828 · 2024: $1,216 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Travel and Lodging: $730 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.04 |
| Travel and Lodging | $729.86 |
| Education | $270.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $914.23 | 2023-2024 | Gi Genius |
| Janssen Biotech, INC. | $748.97 | 2020-2025 | Stelara, Tremfya |
| Abbvie INC. | $673.41 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $417.74 | 2024 | |
| Genzyme Corporation | $242.92 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $150.01 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $124.13 | 2023 | Rebyota |
| Abiomed | $104.03 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.98 | 2019-2023 | Entyvio |
| Celltrion USA INC. | $36.50 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $24.67 | 2019 | |
| Ardelyx, INC. | $24.54 | 2025 | Ibsrela |
| Amgen INC. | $23.73 | 2023 | Avsola |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.